Neflamapimod
Dementia with Lewy Bodies (DLB)
Key Facts
About CervoMed
CervoMed is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases by targeting neuroinflammation-induced synaptic dysfunction, a reversible early-stage pathology. The company's core achievement is positive Phase 2b data for neflamapimod in Dementia with Lewy Bodies (DLB) and alignment with the FDA on a Phase 3 trial design. Its strategy employs a biomarker-informed, precision medicine approach to treat patients at earlier disease stages without significant co-pathology, aiming to demonstrate disease modification where current therapies offer only symptomatic relief.
View full company profileAbout CervoMed
CervoMed is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases by targeting neuroinflammation-induced synaptic dysfunction, a reversible early-stage pathology. The company's core achievement is positive Phase 2b data for neflamapimod in Dementia with Lewy Bodies (DLB) and alignment with the FDA on a Phase 3 trial design. Its strategy employs a biomarker-informed, precision medicine approach to treat patients at earlier disease stages without significant co-pathology, aiming to demonstrate disease modification where current therapies offer only symptomatic relief.
View full company profileAbout CervoMed
CervoMed is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases by targeting neuroinflammation-induced synaptic dysfunction, a reversible early-stage pathology. The company's core achievement is positive Phase 2b data for neflamapimod in Dementia with Lewy Bodies (DLB) and alignment with the FDA on a Phase 3 trial design. Its strategy employs a biomarker-informed, precision medicine approach to treat patients at earlier disease stages without significant co-pathology, aiming to demonstrate disease modification where current therapies offer only symptomatic relief.
View full company profile